➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Express Scripts
Moodys
Boehringer Ingelheim
Baxter

Last Updated: September 23, 2021

DrugPatentWatch Database Preview

Investigational Drug Information for Seribantumab


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Seribantumab?

Seribantumab is an investigational drug.

There have been 7 clinical trials for Seribantumab. The most recent clinical trial was a Phase 1 trial, which was initiated on March 21st 2021.

The most common disease conditions in clinical trials are Breast Neoplasms, Endometrial Neoplasms, and Triple Negative Breast Neoplasms. The leading clinical trial sponsors are Merrimack Pharmaceuticals, Sanofi, and Ottawa Hospital Research Institute.

There are three US patents protecting this investigational drug and eleven international patents.

Recent Clinical Trials for Seribantumab
TitleSponsorPhase
Single Patient Protocol for an NRG1 Fusion Positive Metastatic Pancreatic Cancer Patient Using SeribantumabOttawa Hospital Research InstitutePhase 2
A Phase 2 Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive CancerElevation OncologyPhase 2
Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast CancerMerrimack PharmaceuticalsPhase 2

See all Seribantumab clinical trials

Clinical Trial Summary for Seribantumab

Top disease conditions for Seribantumab
Top clinical trial sponsors for Seribantumab

See all Seribantumab clinical trials

US Patents for Seribantumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Seribantumab ⤷  Try it Free Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors Merrimack Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Try it Free
Seribantumab ⤷  Try it Free Salt of EGFR inhibitor, crystalline form and uses thereof SUNSHINE LAKE PHARMA CO., LTD. (Dongguan, Guangdong, CN) ⤷  Try it Free
Seribantumab ⤷  Try it Free Binding-triggered transcriptional switches and methods of use thereof The Regents of the University of California (Oakland, CA) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Seribantumab

Drugname Country Document Number Estimated Expiration Related US Patent
Seribantumab Australia AU2016343517 2035-10-19 ⤷  Try it Free
Seribantumab Canada CA3001655 2035-10-19 ⤷  Try it Free
Seribantumab China CN106588943 2035-10-19 ⤷  Try it Free
Seribantumab European Patent Office EP3365344 2035-10-19 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Express Scripts
AstraZeneca
Dow
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.